Combination treatment for AML that stays after initial therapy
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of cancer medicines for people with acute myeloid leukemia (AML) that is still detectable after initial treatment. It may help by trying to drive leukemia into a deeper remission when it lingers at low levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 59.
- You must have AML (or AML related to another blood condition) confirmed by bone marrow testing, and it was still detectable at the time of myeloMATCH assignment.
- You finished induction chemotherapy through the myeloMATCH Young Adult program (Tier-1), and you had complete remission or near-complete remission with ongoing detectable minimal residual disease (MRD).
- Your general health score is good (ECOG 0 to 2), and you’ve mostly recovered from side effects of prior treatment (except hair loss).
- Your blood counts and organ tests (liver, kidney) meet minimum lab levels within 7 days before starting, and you can swallow pills.
- If you can become pregnant: you must not be pregnant, use effective birth control during the study and for a set time after, and have a recent pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent, as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works well and is safe.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.